What is Nosopharm?
Nosopharm is a pharmaceutical company focused on developing innovative therapeutic solutions. While the provided description pertains to a lottery data platform, Nosopharm itself is engaged in the critical and complex field of drug discovery and development. The company's trajectory, marked by substantial capital infusions, suggests a strategic focus on advancing its pipeline through rigorous research and clinical trials, aiming to address unmet medical needs.
How much funding has Nosopharm raised?
Nosopharm has raised a total of $3.8M across 2 funding rounds:
Grant
$1.2M
Private Equity
$2.6M
Grant (2013): $1.2M, investors not publicly disclosed
Private Equity (2017): $2.6M led by Auriga Partners, Kreaxi, and Alto Invest
Key Investors in Nosopharm
Auriga Partners
Auriga Partners is a venture capital firm that likely specializes in early-stage technology and life sciences companies, providing crucial seed and growth capital to fuel innovation.
Kreaxi
Kreaxi is an investment management firm specializing in equity financing for innovative and tech startups, with over 30 years of experience. The firm invests between 100k to 2.5m in the initial financing rounds, supporting entrepreneurs during the seed, acceleration, and development phases.
Alto Invest
Alto Invest is a capital management company investing primarily in small and mid-sized fast-growing companies, with a team experienced in managing private equity portfolios on behalf of institutional and private clients.
What's next for Nosopharm?
With a significant strategic investment bolstering its resources, Nosopharm is well-positioned to accelerate its research and development initiatives. The company is likely to focus on advancing its lead candidates through clinical phases, potentially forging strategic partnerships, and expanding its operational capacity. This capital infusion is critical for navigating the lengthy and resource-intensive process of bringing new pharmaceuticals to market, signaling a strong commitment to innovation and growth in the competitive biotech landscape.
See full Nosopharm company page
